People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Arsenal Biosciences, Inc. | — | Biotechnology | Series D+ | $579.2M | $3.5B | 2020 |
| Neumora Therapeutics, Inc. | — | Biotechnology | Growth/Late | $474.4M | $19.0B | 2020 |
| Electra Therapeutics, Inc. | — | Biotechnology | Series D+ | $134.2M | $961.4M | 2025 |
| Star Therapeutics LLC | — | Pharma | Series D+ | $125.0M | $935.3M | 2025 |
Matthew Fust at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Fust on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Beth Seidenberg | 2 | 15 |
| Carl Gordon | 1 | 24 |
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Brook Byers | 1 | 13 |
| Sean Parker | 1 | 10 |
| Jason Hafler | 1 | 6 |
| Maha Katabi | 1 | 6 |
| Nancy Stagliano | 1 | 5 |
| Stacie Weninger | 1 | 4 |
| Scott Robertson | 1 | 3 |
| Paul Berns | 1 | 3 |
| Beth Seidenberg, M.D. | 1 | 3 |
| MAYKIN HO | 1 | 2 |
| Carl Gordon, Ph.D. | 1 | 2 |
| Michelle Carpenter | 1 | 2 |
| Tamara Tompkins | 1 | 2 |
| Alaa Halawa | 1 | 2 |
| James Ahlers | 1 | 2 |
| Amrit Nagpal | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.